Anandamide prodrugs: 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide

European Journal of Pharmaceutical Sciences

Volumn 19, Issue 1, 2003, Pages 37-43

  Juntunen, Juha ^a   Huuskonen, Juhani ^a   Laine, Krista ^a   Niemi, Riku ^a   Taipale, Hannu ^a   Nevalainen, Tapio ^a   Pate, David W ^b   Järvinen, Tomi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b HortaPharm BV   (Netherlands)

Author keywords

Anandamide; Arachidonylethanolamide; Cannabinoid; Phosphate ester; Prodrugs; Water soluble

Indexed keywords

ENZYMES; ESTERS; HYDROLYSIS; PH EFFECTS; SYNTHESIS (CHEMICAL);

INTRAOCULAR PRESSURE (IOP);

DRUG PRODUCTS;

ALKALINE PHOSPHATASE; ANANDAMIDE; BUFFER; EYE DROPS; METHANANDAMIDE; ORGANOPHOSPHATE; PHOSPHORIC ACID [2 (EICOSA 5,8,11,14 TETRAENOYLAMINO)ETHYL]ESTER; PHOSPHORIC ACID [2 (EICOSA 5,8,11,14 TETRAENOYLAMINO)PROPYL]ESTER; PRODRUG; UNCLASSIFIED DRUG; WATER;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; INTRAOCULAR PRESSURE; LIVER HOMOGENATE; MALE; NONHUMAN; PARTITION COEFFICIENT; PH; PRIORITY JOURNAL; RABBIT;

EID: 0037406988     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(03)00044-7     Document Type: Article

References (24)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. Adams I.B., Ryan W., Singer M., Razdan R.K., Compton D.R., Martin B.R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56:1995;2041-2048.
3. Avdeef A. pH-Metric log P. II: Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 82:1993;183-190.
4. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
5. Cabral G.A., Toney D.M., Fisher-Stenger K., Harrison M.P., Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci. 56:1995;2065-2072.
6. Cho M.J., Kurtz R.R., Lewis C., Machkovech S.M., Houser D.J. Metronidazole phosphate-water soluble prodrug for parenteral solutions of metronidazole. J. Pharm. Sci. 71:1982;410-414.
7. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
8. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
9. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
10. Fernandez M.P., Gascon S., Schwncke J. Some enzymatic properties of vacuolar alkaline phosphatase from yeast. Curr. Microbiol. 6:1981;121-126.
11. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
12. Hopper D.W., Catalano J.G., Macdonald T.L. Facile synthesis of lysophospholipids containing unsaturated fatty acid chains. Tetrahedron Lett. 37:1996;7871-7874.
13. Jadhav P.K., Woerner F.J., Aungst B.J. Synthesis of water soluble prodrug of DMP323. Bioorg. Med. Chem. Lett. 6:1996;2259-2262.
14. Jarho P., Urttti A., Järvinen K., Pate D.W., Järvinen T. Hydroxypropyl-β-cyclodextrin increases aqueous solubility and stability of anandamide. Life Sci. 58:1996;181-185.
15. Laine K., Järvinen K., Pate D.W., Urtti A., Järvinen T. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Invest. Ophthalmol. Vis. Sci. 43:2002;393-397.
16. Pate D.W., Järvinen K., Urtti A., Jarho P., Järvinen T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr. Eye Res. 14:1995;791-797.
17. Pate D.W., Järvinen K., Urtti A., Mahadevan V., Järvinen T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 63:1998;2181-2188.
18. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:1999;635-664.
19. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp. Opin. Invest. Drugs. 9:2000;1-19.
20. Sheskin T., Hanuš L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
21. Simopoulos T.T., Jencks W.P. Alkaline phosphatase is an almost perfect enzyme. Biochemistry. 33:1994;10375-10380.
22. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
23. Varia S.A., Schuller S., Sloan K.B., Stella V.J. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73:1984;1068-1073.
24. Wenger T., Tóth B.E., Martin B.R. Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci. 56:1995;2057-2063.